EP0000896B1 - Propenyl amines, processes for their production and pharmaceutical compositions containing them - Google Patents

Propenyl amines, processes for their production and pharmaceutical compositions containing them Download PDF

Info

Publication number
EP0000896B1
EP0000896B1 EP78100611A EP78100611A EP0000896B1 EP 0000896 B1 EP0000896 B1 EP 0000896B1 EP 78100611 A EP78100611 A EP 78100611A EP 78100611 A EP78100611 A EP 78100611A EP 0000896 B1 EP0000896 B1 EP 0000896B1
Authority
EP
European Patent Office
Prior art keywords
formula
radical
alkyl
hydrogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP78100611A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0000896A2 (en
EP0000896A3 (en
Inventor
Helmut Dr. Hamberger
Adrian Dr. Stephen
Anton Dr. Stütz
Peter Dr. Stütz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27429271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0000896(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CH1020377A external-priority patent/CH632251A5/de
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of EP0000896A2 publication Critical patent/EP0000896A2/en
Publication of EP0000896A3 publication Critical patent/EP0000896A3/xx
Application granted granted Critical
Publication of EP0000896B1 publication Critical patent/EP0000896B1/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms

Definitions

  • This invention relates to propenyl-amines, processes for their production and pharmaceutical compositions containing them.
  • the present invention provides a compound of formula I, wherein
  • lower alkyl or “lower alkoxy” radical mean containing 1 to 4 carbon atoms, especially 2 or 1 carbon atoms.
  • Any alkyl (C 1 ⁇ 12 ) moiety is preferably alkyl (C 2 ⁇ 8 ); phenylalkyl or phenylalkoxy has preferably 7 carbon atoms.
  • Any alkenyl or alkynyl radical has preferably 3 to 6 carbon atoms, especially 3 or 4 carbon atoms.
  • the multiple bond is in other than the ⁇ , ⁇ position and is conveniently in the remote terminal position.
  • An example of an alkenyl group is allyl.
  • An example of an alkynyl group is propinyl.
  • Cycloalkylalkyl has preferably an alkyl moiety of 1 to 4 carbon atoms, especially 2 or 1 carbon atoms, and a cycloalkyl moiety preferably of 3 to 6 carbon atoms.
  • R 4 is cycloalkylalkyl this is especially cyclopentyl alkyl or cyclohexylalkyl.
  • R 10 is cycloalkylalkyl this is especially cyclopropylalkyl or cyclobutylalkyl.
  • R 7 and R 8 are identical and are both hydrogen.
  • R 9 is hydrogen or halogen.
  • IIb and IIc the bond to the carbon atom to which R 2 and R 3 are attached is conveniently attached meta to X and para to the ring nitrogen, respectively.
  • X is conveniently sulphur, imino or lower alkylamino.
  • R 1 is preferably a radical of formula IIb, IIc or IId or especially IIa.
  • R 2 is preferably hydrogen.
  • R 3 is preferably hydrogen and R 4 is conveniently alkyl.
  • R 5 is conveniently hydrogen.
  • R 6 when it is a heterocycle, conveniently contains one oxygen or sulphur atom or one or two nitrogen atoms.
  • the bond linking R 6 to the vinylene moiety is attached to a ring carbon atom adjacent to a ring heteroatom.
  • the ring is unsubstituted or substituted by lower alkyl.
  • R 10 is conveniently phenylalkoxy.
  • IIIa is conveniently optionally substituted 2 or 4-pyridyl.
  • IIIc, IIId, IIIe it is to be appreciated that the bond linking R 6 to the vinylene moiety and R 11 to R 13 may be attached to any of the ring carbon atoms present.
  • IIIc is preferably a cycloalk-1-en-1-yl radical.
  • R 11 to R 13 are hydrogen.
  • q is conveniently 0 or 1. Any double bond in IIIf is conveniently trans.
  • R 14 is conveniently alkoxy (C 1 ⁇ 8 ) carbonyl, phenyl or alkyl or phenalkyl.
  • R 17 is conveniently halogen and R 18 is conveniently hydrogen.
  • R 6 is conveniently IIIc.
  • u is conveniently 3, 4 or 5, more conveniently 4.
  • m, n, p, q, s, t and v are conveniently chosen to produce a five or six-membered ring.
  • the double bond between R 6 and the nitrogen atom preferably has the trans configuration.
  • Halogen is conveniently fluorine, or preferably bromine or chlorine.
  • R 1 is IIb or IIe and R 6 is IIIa it is to be appreciated that the two radicals R 9 may be the same or different.
  • the present invention also provides a process for the production of a compound of formula I, selected from
  • Process a) may be effected in conventional manner for the production of tertiary amines by condensation from analogous starting materials.
  • the process may be effected in an inert solvent such as a lower alkanol, e.g. ethanol, optionally in aqueous admixture, an aromatic hydrocarbon solvent, e.g. benzene or toluene, a cyclic ether, e.g. dioxane or a carboxylic acid dialkylamide solvent, e.g. dimethylformamide.
  • the reaction temperature is conveniently from room temperature to the boiling temperature of the reaction mixture, preferably room temperature.
  • the reaction is conveniently effected in the presence of an acid binding agent, such as an alkali metal carbonate, e.g.
  • the leaving group A is conveniently iodine or preferably chlorine or bromine, or an organic sulphonyloxy group having 1 to 10 carbon atoms, e.g. alkylsulphonyloxy, preferably having 1 to 4 carbon atoms such as mesyloxy, or alkylphenylsulphonyloxy preferably having 7 to 10 carbon atoms such as tosyloxy.
  • Process b) may be effected in conventional manner for catalytic hydrogenation in order to produce a compound of formula I wherein the double bond adjacent to R 6 has the cis configuration.
  • the process may be effected in conventional manner for a complex metal hydride reduction in order to produce a compound of formula I wherein the double bond has the trans configuration.
  • the catalytic hydrogenation may be effected in a solvent, e.g. methanol, ethanol, methylene chloride, pyridine or ethyl acetate.
  • the catalyst is preferably palladium on a carrier material such as BaS0 4 or CaC0 3 .
  • the catalyst may be pretreated, e.g. with a lead salt, so as to be partially poisoned (e.g. a Lindlar catalyst).
  • the hydrogenation may be effected at room temperature and at normal pressure.
  • the metal hydride reduction may be effected in conventional manner for a lithium aluminium -hydride or a diisobutylaluminium hydride reduction.
  • the reduction is conveniently effected in an inert solvent such as toluene or benzene.
  • the reaction is conveniently effected at room temperature.
  • Process c) may be effected in conventional manner for a photochemical isomerisation of a cis alkene.
  • the reaction may be effected in a solvent such as benzene, petroleum ether, ethanol, or preferably cyclohexane.
  • the solution is conveniently irradiated with light from a mercury high or low pressure lamp.
  • the reaction is conveniently effected at room temperature.
  • an appropriate sensitizer such as eosine or a catalyst such as diphenyldisulphide may be present.
  • Process d) may be effected in manner conventional for the "alkylation" of secondary amines (the term “alkylation” being used here to denote introduction of any of the hydrocarbyl groups R 4 ), for example by direct “alkylation” with an “alkylating” agent, for example a halide or sulphate, or by reductive alkylation, in particular by reaction with an appropriate aldehyde and subsequent or simultaneous reduction.
  • Reductive "alkylation” is suitably effected in an inert organic solvent, such as a lower alkanol, e.g. methanol, and at an elevated temperature, in particular at the boiling temperature of the reaction medium.
  • the subsequent reduction may be effected with, for example, a complex metal hydride reducing agent, e.g. NaBH 4 or LiAIH 4 .
  • a complex metal hydride reducing agent e.g. NaBH 4 or LiAIH 4 .
  • the reduction may also be effected simultaneously to the alkylation, for example by use of formic acid which may serve both as reducing agent and as a reaction medium.
  • side reactions may occur, e.g. reduction of halogen to hydrogen, reduction of a nitro group to an amino group, reduction of an alkenyl moiety to an alkyl moiety and/or reduction of a keto moiety to a carbinol moiety in processes b) or process d) when reductive alkylation is used, or simultaneous cis/trans isomerisation of any double bond present in R 4 or R 6 when process c) is used.
  • the reaction conditions should be chosen to avoid such side reactions, and the desired final product isolated using conventional purification techniques, e.g. thin layer chromatography.
  • Free base forms of the compounds of formula I may be converted into salt forms and vice versa.
  • Suitable acids for acid addition salt formation include hydrochloric acid, fumaric acid and naphthalene-1,5-disulphonic acid.
  • non-cyclic amines of formula IV may be made by condensing a compound of formula VIII, or the corresponding iodide or chloride, with a compound of formula R 4 NH 2 .
  • cyclic amines of formula IV may be made as follows:- wherein
  • Alk lower alkyl
  • the compounds of formula VI are new and may be made by reacting an appropriate amine of formula IV with compounds of formulae R 5 ⁇ CHO and under Mannich reaction conditions.
  • the title compound may also be made in analogous manner to Examples 3, 4 and 5.
  • the title compound may also be made in analogous manner to Examples 1 and 5.
  • the title compound may also be prepared by following Examples 1, 4 and 5.
  • the title compound may also be prepared by following Examples 1, 3 and 5.
  • the title compound may also be prepared in analogous manner to Examples 1, 3 and 4.
  • NMR data on the above-mentioned compounds of formula I, obtained as oils, are given in the following table.
  • the compounds of formula I exhibit chemotherapeutic activity.
  • they exhibit antimycotic activity, as indicated in vitro with tests against various families and types of mycetes, including Trichophton quinkeanum, Aspergillus fumigatus, Microsporum canis Sporotrychium schenkii and Candida albicans, at concentrations of, for example 0.1 to 100 ⁇ g/ml, and in vivo in the experimental skin mycosis model in guinea pigs. In the latter model, guinea pigs are infected by cutaneous application of Trichophyton quinkeanum.
  • test substance is administered daily for 7 days beginning 24 hours after the infection by local application by rubbing the test substance (taken up in polyethylene glycol) on the skin surface, or perorally, the test substance being administered as a suspension.
  • the activity is shown on local application at concentrations of from example 0.1 to 2%, in particular 0.1 to 0.6%.
  • the oral activity is shown at dosages of, for example, 50 to 100 mg/kg.
  • the compounds are therefore indicated for use as anti-mycotic agents.
  • daily dose is from 500 to 2000 mg. If desired, this may be administered in divided doses 2 to 4 times a day in unit dosage form containing from about 125 mg to about 1000 mg or in sustained release form.
  • the compounds may be used in free base form or in the form of chemotherapeutically acceptable acid addition salts. Such salt forms exhibit the same order of activity as the free base forms.
  • the compounds may be admixed with conventional chemotherapeutically acceptable diluents and carriers, and, optionally, other excipients and administered in such forms as tablets or capsules.
  • the compounds may alternatively be administered topically in such conventional forms as ointments or creams.
  • concentration of the active substance in such topical application forms will of course vary depending on the compound employed, the treatment desired and the nature of the form etc. In general, however, satisfactory results are obtained at concentrations of from 0.05 to 3, in particular 0.1 to 1 wt 96.
  • a compound with particularly interesting activity is the compound of Example 4.
  • One group of compounds has a formula Ig, wherein
  • Another group of compounds comprises those of formula Ih, wherein
  • a further group of formula I compounds comprises compounds of formula li, wherein

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrrole Compounds (AREA)
EP78100611A 1977-08-19 1978-08-07 Propenyl amines, processes for their production and pharmaceutical compositions containing them Expired EP0000896B1 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CH10203/77 1977-08-19
CH1020377A CH632251A5 (en) 1977-08-19 1977-08-19 Process for preparing novel 2-naphthyl-substituted, cyclic, N-allylamine derivatives
CH1020277 1977-08-19
CH10202/77 1977-08-19
CH12909/77 1977-10-24
CH12910/77 1977-10-24
CH1290977 1977-10-24
CH1291077 1977-10-24

Publications (3)

Publication Number Publication Date
EP0000896A2 EP0000896A2 (en) 1979-03-07
EP0000896A3 EP0000896A3 (en) 1979-05-30
EP0000896B1 true EP0000896B1 (en) 1982-10-13

Family

ID=27429271

Family Applications (1)

Application Number Title Priority Date Filing Date
EP78100611A Expired EP0000896B1 (en) 1977-08-19 1978-08-07 Propenyl amines, processes for their production and pharmaceutical compositions containing them

Country Status (14)

Country Link
US (1) US4680291A (enrdf_load_stackoverflow)
EP (1) EP0000896B1 (enrdf_load_stackoverflow)
JP (1) JPS5441855A (enrdf_load_stackoverflow)
CA (1) CA1111852A (enrdf_load_stackoverflow)
DE (1) DE2862103D1 (enrdf_load_stackoverflow)
DK (1) DK152114C (enrdf_load_stackoverflow)
ES (1) ES472641A1 (enrdf_load_stackoverflow)
FI (1) FI65774C (enrdf_load_stackoverflow)
IE (1) IE47314B1 (enrdf_load_stackoverflow)
IL (1) IL55382A (enrdf_load_stackoverflow)
IT (1) IT1098253B (enrdf_load_stackoverflow)
MY (1) MY8500040A (enrdf_load_stackoverflow)
NZ (1) NZ188170A (enrdf_load_stackoverflow)
PT (1) PT68448A (enrdf_load_stackoverflow)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3020113A1 (de) * 1979-06-08 1980-12-18 Sandoz Ag 2-(1-naphthyl)piperidin-derivat, dessen herstellung sowie die verwendung als antimykotika
DE19975055I1 (de) * 1979-08-22 2000-01-27 Novartis Ag Propenylamine Verfahren zu ihrer Herstellung sie enthaltende pharmazeutische Zusammensetzungen und ihre Verwending als Arzneimittel
NL8003141A (nl) * 1980-05-30 1982-01-04 Akzo Nv Biologisch aktieve tricyclische aminen.
IT1150211B (it) * 1981-03-02 1986-12-10 Abbott Lab 1,2,3,4-tetraidronaftaleni sostituiti con amminoalchili adazione farmaceutica
CH653028A5 (de) * 1982-02-03 1985-12-13 Sandoz Ag Benzthiophenallylamin-verbindungen und verfahren zu ihrer herstellung.
JPS6145A (ja) * 1984-06-09 1986-01-06 Kaken Pharmaceut Co Ltd Ｎ‐（４‐ｔｅｒｔ‐ブチルベンジル）‐Ｎ‐メチル‐１‐ナフチルメチルアミンおよびそれを有効成分とする抗真菌剤
US5334628A (en) * 1984-06-09 1994-08-02 Kaken Pharmaceutical Co., Ltd. Amine derivatives, processes for preparing the same and fungicides containing the same
JPH0676285B2 (ja) * 1985-11-01 1994-09-28 三井東圧化学株式会社 ベンジルアミン誘導体、その製造法およびその用途
EP0254677A1 (en) * 1986-07-08 1988-01-27 Sandoz Ag Antimycotic 6-phenyl-2-hexen-4-ynamines
US5084476A (en) * 1986-07-15 1992-01-28 Hoffmann-La Roche Inc. Tetrahydronaphthalene and indane derivatives
US5234946A (en) * 1987-11-27 1993-08-10 Banyu Pharmaceutical Co., Ltd. Substituted alkylamine derivatives
JPH03105465U (enrdf_load_stackoverflow) * 1990-02-16 1991-10-31
GB9513750D0 (en) * 1995-07-06 1995-09-06 Sandoz Ltd Use of allylamines
CN1228084A (zh) * 1996-08-01 1999-09-08 道农业科学公司 具有杀菌活性的4－取代的喹啉衍生物
US6117884A (en) * 1997-07-31 2000-09-12 Daeuble; John 4-substituted quinoline derivatives having fungicidal activity
JP4509327B2 (ja) * 2000-08-03 2010-07-21 ダイセル化学工業株式会社 Ｎ，ｎ−ジ置換−４−アミノクロトン酸エステルの製造方法
GB0320312D0 (en) * 2003-08-29 2003-10-01 Novartis Ag Purification process
US20050197512A1 (en) * 2003-08-29 2005-09-08 Ulrich Beutler Purification process
BRPI0512841A (pt) * 2004-07-02 2008-01-08 Warner Lambert Co composições e métodos para o tratamento de infecções patológicas
RU2274635C1 (ru) * 2004-12-29 2006-04-20 Федеральное государственное предприятие Государственный научно-исследовательский институт органической химии и технологии (ФГУП ГосНИИОХТ) Способ получения тербинафина или его гидрохлорида
CA2615799A1 (en) * 2005-07-21 2007-02-01 Nomir Medical Technologies, Inc. Near infrared microbial elimination laser system (nimels)
US20090082469A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched terbinafine
CN107531613B (zh) * 2016-02-03 2021-02-05 华东理工大学 苯并脂肪环取代烷基胺类化合物及其用途
CN108084125B (zh) * 2016-11-23 2020-08-18 华东理工大学 苯并杂环烷基胺类化合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE609151C (de) * 1930-02-01 1935-02-08 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von Aminoalkoholen mit sekundaerer oder tertiaerer Aminogruppe
US2601275A (en) * 1949-10-29 1952-06-24 Givaudan Corp Aromatic chlorethylamines and their salts
DK106378C (da) * 1962-10-19 1967-01-30 Koninklijke Pharma Fab Nv Fremgangsmåde til fremstilling af N-substituerede 1-phenyl-2-aminoalkaner eller syreadditionssalte heraf.
GB1041987A (en) * 1964-09-03 1966-09-07 Beecham Group Ltd Acetylenic compounds
GB1134715A (en) * 1966-02-24 1968-11-27 Geistlich Soehne Ag Bisphenylalkenylamine derivatives
US3784642A (en) * 1967-11-03 1974-01-08 E Jenny 1-amine-cyclobutene
BE786748A (fr) * 1971-07-26 1973-01-26 Basf Ag 1-aminomethyl-indanes-n-substitues
BE791133A (fr) * 1971-11-10 1973-05-09 Calgon Corp Nouveaux monomeres cationiques et leurs procedes de fabrication
BE791538A (fr) * 1971-11-19 1973-05-17 Basf Ag 1-aminomethyl-acenaphtenes, leur preparation et leurs utillisations therapeutiques
BE794598A (fr) * 1972-01-28 1973-05-16 Richardson Merrell Inc Nouveaux derives olefiniques de piperidines substituees en 4 et leur procede de preparation
JPS4930346A (enrdf_load_stackoverflow) * 1972-07-18 1974-03-18
US4139560A (en) * 1974-02-22 1979-02-13 Ciba Geigy Corporation Nonylamines
HU169507B (enrdf_load_stackoverflow) * 1974-09-25 1976-12-28
DE2716943C2 (de) * 1976-04-28 1986-08-14 Sandoz-Patent-GmbH, 7850 Lörrach N-(3-Phenyl-2-propenyl)-N-(1-naphthylmethyl)-amine, ihre Verwendung und Herstellung

Also Published As

Publication number Publication date
IT1098253B (it) 1985-09-07
EP0000896A2 (en) 1979-03-07
EP0000896A3 (en) 1979-05-30
NZ188170A (en) 1981-05-01
FI65774C (fi) 1984-07-10
US4680291A (en) 1987-07-14
JPS6317050B2 (enrdf_load_stackoverflow) 1988-04-12
JPS5441855A (en) 1979-04-03
ES472641A1 (es) 1979-10-16
DK152114B (da) 1988-02-01
CA1111852A (en) 1981-11-03
FI782446A7 (fi) 1979-02-20
PT68448A (fr) 1978-09-01
IL55382A (en) 1981-12-31
FI65774B (fi) 1984-03-30
IT7826835A0 (it) 1978-08-18
IE781670L (en) 1979-02-19
IL55382A0 (en) 1978-10-31
MY8500040A (en) 1985-12-31
DE2862103D1 (en) 1982-11-18
DK354678A (da) 1979-02-20
IE47314B1 (en) 1984-02-22
DK152114C (da) 1988-06-20

Similar Documents

Publication Publication Date Title
EP0000896B1 (en) Propenyl amines, processes for their production and pharmaceutical compositions containing them
EP0024587B1 (en) Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
CA2004575A1 (en) 2-amino-4 or 5-methoxycyclohexyl amides useful as analgesics
EP0288188A1 (en) 1-Phenyl-3-naphthalenyloxy-propanamines
IE46278B1 (en) Piperazine derivatives
CA2541066C (fr) Derives d'indanyl-piperazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IE45727B1 (en) Aralkenylaminomethyl-naphthalene derivatives
CH644582A5 (fr) Amides d'acide polyprenylcarboxylique.
US5132459A (en) Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
CA1049530A (en) Diphenylpropylamines
EP0230020B1 (en) 1,2,3,4,4a,9b-hexahydro-4a-aminoalkyldibenzofurans, a process for their preparation and their use as medicaments
US3972935A (en) Antiarrhythmic agents
US3963780A (en) N,N'-disubstituted-p-phenylenediamines
US3819708A (en) N,n'-disubstituted-p-phenylenediamines
US3228984A (en) 1, 4-bis-cyclic and aryl-amino-[2.2.2] bicyclooctane derivatives
US5317026A (en) Acetamide derivative and application thereof
US3997608A (en) N-substituted-dihydroxyphenethylamines
US3888829A (en) N,n'-bis(3-hydroxy-2-(3,4-dihydroxy-phenyl)-1-propyl)-aliphatic-diamines
EP0246077B1 (en) Heteropolycyclic aromatic compounds
US3674807A (en) 1-p-(omega-aminoalkyl)phenyl-cyclohexanes,cyclohexenes and cyclohexanols
EP0000825B1 (en) Geminally disubstituted indene derivatives, processes for their preparation and pharmaceutical compositions containing them
US4542022A (en) Silyl-alkyn-en-ylamine derivatives
EP0318234A2 (en) Improvements in or relating to selective serotonin uptake inhibitors
US2992231A (en) Pyrrolidyl derivatives of 3-arylindenes and 3-arylindanes
US3957871A (en) Chemical compounds and the process for preparing same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): BE CH DE FR GB LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Designated state(s): BE CH DE FR GB LU NL SE

17P Request for examination filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): BE CH DE FR GB LU NL SE

REF Corresponds to:

Ref document number: 2862103

Country of ref document: DE

Date of ref document: 19821118

EPTA Lu: last paid annual fee
EAL Se: european patent in force in sweden

Ref document number: 78100611.9

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Free format text: SANDOZ AG TRANSFER- NOVARTIS AG

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19970602

Year of fee payment: 20

Ref country code: FR

Payment date: 19970602

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19970604

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19970605

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19970609

Year of fee payment: 20

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19970630

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19970707

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19970813

Year of fee payment: 20

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

BE20 Be: patent expired

Free format text: 980807 *SANDOZ A.G.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19980806

Ref country code: CH

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19980806

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19980807

Ref country code: LU

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19980807

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19980808

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Effective date: 19980806

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 19980807

EUG Se: european patent has lapsed

Ref document number: 78100611.9

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT